Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients
暂无分享,去创建一个
[1] J. J. de la Rosette,et al. Weak association between arterial hypertension and overactive bladder baseline symptoms and treatment responses , 2022, Frontiers in Pharmacology.
[2] M. Kas,et al. The EQIPD framework for rigor in the design, conduct, analysis and documentation of animal experiments , 2022, Nature Methods.
[3] A. Grechko,et al. Hypertension as a risk factor for atherosclerosis: Cardiovascular risk assessment , 2022, Frontiers in Cardiovascular Medicine.
[4] A. Kannt,et al. Analysis of 16 studies in nine rodent models does not support the hypothesis that diabetic polyuria is a main reason of urinary bladder enlargement , 2022, Frontiers in Physiology.
[5] P. Fornara,et al. Associations between the Patient Perception of Bladder Condition score and overactive bladder syndrome symptoms at baseline and upon treatment , 2022, Neurourology and urodynamics.
[6] Guiming Liu,et al. Established and emerging treatments for diabetes-associated lower urinary tract dysfunction , 2022, Naunyn-Schmiedeberg's Archives of Pharmacology.
[7] J. J. de la Rosette,et al. What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine , 2022, Advances in Therapy.
[8] P. Thürmann,et al. Trends and patterns in EU(7)-PIM prescribing to elderly patients in Germany , 2021, European Journal of Clinical Pharmacology.
[9] M. Oelke,et al. Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a Non-Interventional Setting , 2021, Journal of clinical medicine.
[10] J. J. de la Rosette,et al. Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study , 2020, Frontiers in Pharmacology.
[11] U. Dirnagl,et al. Systematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animals , 2020, BMJ Open Science.
[12] A. Stang,et al. Do overactive bladder symptoms and their treatment‐associated changes exhibit a normal distribution? Implications for analysis and reporting , 2020, Neurourology and urodynamics.
[13] Martin C Michel,et al. New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology , 2019, Drug Metabolism and Disposition.
[14] H. Motulsky,et al. New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology , 2019, Molecular Pharmacology.
[15] S. Greenland,et al. Scientists rise up against statistical significance , 2019, Nature.
[16] M. Michel,et al. A systematic review of urinary bladder hypertrophy in experimental diabetes: Part 2. Comparison of animal models and functional consequences , 2018, Neurourology and urodynamics.
[17] M. Michel,et al. A systematic review of urinary bladder hypertrophy in experimental diabetes: Part I. Streptozotocin‐induced rat models , 2018, Neurourology and urodynamics.
[18] Bing Yang*,et al. The Relationship between the Clinical Progression of Benign Prostatic Hyperplasia and Metabolic Syndrome: A Prospective Study , 2016, Urologia Internationalis.
[19] K. Azadzoi,et al. LUTS in pelvic ischemia: a new concept in voiding dysfunction. , 2016, American journal of physiology. Renal physiology.
[20] J. Lang,et al. A Population-based Survey of the Prevalence, Potential Risk Factors, and Symptom-specific Bother of Lower Urinary Tract Symptoms in Adult Chinese Women. , 2015, European urology.
[21] R. Chess-Williams,et al. Are blood vessels a target to treat lower urinary tract dysfunction? , 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.
[22] L. Cardozo,et al. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies , 2015, International journal of clinical practice.
[23] E. Barrett-Connor,et al. Lifestyle and Health Factors Associated with Progressing and Remitting Trajectories of Untreated Lower Urinary Tract Symptoms among Elderly Men , 2014, Prostate Cancer and Prostatic Disease.
[24] M. Michel,et al. Does concomitant diabetes affect treatment responses in overactive bladder patients? , 2013, International journal of clinical practice.
[25] T. Golabek,et al. Detrusor overactivity in diabetic and non-diabetic patients: is there a difference? , 2012, International braz j urol : official journal of the Brazilian Society of Urology.
[26] R. Freeman,et al. Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes , 2011, Diabetes/metabolism research and reviews.
[27] G. De Nucci,et al. Characterization of the urinary bladder dysfunction in renovascular hypertensive rats , 2011, Neurourology and urodynamics.
[28] Matthew T. Haren,et al. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men , 2011, World Journal of Urology.
[29] T. Schneider,et al. Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients? , 2010, International journal of clinical practice.
[30] C. Porto,et al. Long‐term nitric oxide deficiency causes muscarinic supersensitivity and reduces β3‐adrenoceptor‐mediated relaxation, causing rat detrusor overactivity , 2008, British journal of pharmacology.
[31] C. Roehrborn,et al. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. , 2006, Urology.
[32] S. Madersbacher,et al. The association between vascular risk factors and lower urinary tract symptoms in both sexes. , 2006, European urology.
[33] E. Giovannucci,et al. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III) , 2005, International Journal of Obesity.
[34] U. Heemann,et al. Association of hypertension with symptoms of benign prostatic hyperplasia. , 2004, The Journal of urology.
[35] Michael A. Joseph,et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. , 2003, American journal of epidemiology.
[36] M. Michel,et al. Does gender or age affect the efficacy and safety of tolterodine? , 2002, The Journal of urology.
[37] M. Barry,et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. , 2001, Journal of clinical epidemiology.
[38] P. Abrams,et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study , 2001, BJU international.
[39] H. Schumacher,et al. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. , 2000, The Journal of urology.
[40] W. Steers,et al. Altered NGF regulation may link a genetic predisposition for hypertension with hyperactive voiding. , 1999, The Journal of urology.
[41] W. Steers,et al. The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males , 1999, Experimental physiology.
[42] W. Steers,et al. Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. , 1998, The American journal of physiology.
[43] H. Schumacher,et al. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? , 1998, The Journal of urology.
[44] W. Steers,et al. Neurally mediated hyperactive voiding in spontaneously hypertensive rats , 1998, Brain Research.
[45] U. Wetterauer,et al. Cardiovascular Safety and Overall Tolerability of Solifenacin in Routine Clinical Use , 2008, Drug safety.
[46] U. Heemann,et al. Safety of Telmisartan in Patients with Arterial Hypertension , 2004, Drug safety.
[47] Carolyn Margraf,et al. Overactive bladder. , 2002, The American journal of nursing.